Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-04-2024 | Denosumab | Case report

Denosumab/zoledronic-acid

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Patel R, et al. Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?. Journal of the Endocrine Society 4 (Suppl.): A962 abstr. MON-335, May 2020. Available from: URL: https://dx.doi.org/10.1210/jendso/bvaa046.1908 [abstract] Patel R, et al. Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?. Journal of the Endocrine Society 4 (Suppl.): A962 abstr. MON-335, May 2020. Available from: URL: https://​dx.​doi.​org/​10.​1210/​jendso/​bvaa046.​1908 [abstract]
Metadata
Title
Denosumab/zoledronic-acid
Lack of efficacy
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56799-y

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

BBIBP CorV

Case report

Alogliptin

Case report

Phenylephrine

Case report

Rituximab